key: cord-0303193-dzmcvhaz
authors: Planès, Rémi; Bert, Jean-Baptiste; Tairi, Sofiane; Benmohamed, Lbachir; Bahraoui, Elmostafa
title: SARS-CoV-2 Envelope protein (E) binds and activates TLR2: A novel target for COVID-19 interventions
date: 2021-11-12
journal: bioRxiv
DOI: 10.1101/2021.11.10.468173
sha: b353bf1843e23ad97500117e6a05ef727da10b6a
doc_id: 303193
cord_uid: dzmcvhaz

In this study, we present a molecular characterization of the interaction between the SARS-CoV-2 envelope protein E with TLR2. We demonstrated that E protein interacts physically with TLR2 receptor in a specific and dose-dependent manner. Furthermore, we showed that this interaction is able to engage TLR2 pathway as demonstrated by its capacity to activate NF-κB transcription factor and to stimulate the production of CXCL8 inflammatory chemokine in a TLR2-dependent manner. Furthermore, in agreement with the importance of NF-κB in TLR signaling pathway, we showed that the chemical inhibition of this transcription factor led to significant inhibition of CXCL8 production, while blockade of P38 and ERK1/2 MAP kinases resulted only in a partial CXCL8 inhibition. Overall, our findings suggest considering the envelope protein E as a novel target for COVID-19 interventions: (i) either by exploring the therapeutic effect of anti-E blocking/neutralizing antibodies in symptomatic COVID-19 patients, or (ii) as a promising non-Spike SARS-CoV-2 antigen candidate to include in the development of next generation prophylactic vaccines against COVID-19 infection and disease. Importance Although, the exact mechanisms of COVID-19 pathogenesis are unknown, recent data demonstrated that elevated levels of pro-inflammatory cytokines in serum is associated with enhanced disease pathogenesis and mortality. Thus, determining the molecular mechanisms responsible for inflammatory cytokine production in the course of SARS-CoV-2 infection could provide future therapeutic targets. In this context, to the best of our knowledge, our report is first to use a detailed molecular characterization to demonstrate that SARS-CoV-2 Envelope E protein binds to TLR2 receptor. Specifically, we showed that SARS-CoV-2 Envelope E protein binds to TLR2 in a direct, specific and dose-dependent manner. Investigating signalling events that control downstream activation of cytokine production show that E protein / TLR2 binding leads to the activation of NF-κB transcription factor that control the expression of multiple pro-inflammatory cytokines including CXCL8. Overall, our findings suggest considering the envelope protein E as a novel target for COVID-19 interventions.

SARS-CoV-2, the etiologic agent of the current worldwide COVID-19 pandemic, is a (8, 9) . Thus, the important role of E protein, makes it as potential 65 target for antiviral drug molecules and vaccine candidates development (10). Protein-protein 66 interactions were well characterized between E and M proteins, as shown by the presence of 67 E-M complexes at the level of ERGIC in infected cells (11, 12) . It is also interesting to note 68 that the expression of these two proteins is sufficient for the formation of VLP (viral like 69 particles) (6, 13). By interfering with protein transport via secretory pathways and with the 70 normal function of the immune system, E protein could act as a pathogenic factor in the 71 immunopathogenesis associated with SARS-CoV, 14) . In 72 fact, in SARS-CoV infected cells, E protein anchored to a lipid bilayer is able to adopt a 73 structure forming membrane-integral pores, also named viroporin, with a selective activity for 74 cations including, H+, K+, Na+ and Ca2+ (15) . At least, the selective permeability to Ca2+ 75 has been reported to be associated with the inflammatory response often observed in ARDS 76 (acute respiratory distress syndrome) (15).

Infection with SARS-CoV-2 is accompanied by deregulation of the control 78 mechanisms of the innate immune response (16, 17) . This deregulation is characterized by a 79 delay in the IFN-I and III production and also by an exacerbation of the inflammatory 80 response including, IL-6, TNF-α, IL-1β, IFN-γ but also certain chemokines including CXCL8 81 (18). In patients developing a critical COVID-19, this dysregulation leads to the establishment 82 of a cytokine storm, a deleterious proapoptotic state for various tissues and organs including 83 the lungs (19) (20) (21) . SARS-CoV-2 infection also impact the adaptative immune response by 84 affecting the normal physiological functions of antigenic presenting cells (22), but also CD4+, 85 and in a higher degree CD8+ T-cells(23, 24) .

Understanding the molecular mechanisms responsible, on one hand, for the control or that SARS-CoV-2 E envelope protein can be sensed by TLR2 (31), and its expression, as that 105 of its cofactor MyD88, and the induced inflammatory responses seem to increase more 106 importantly in patients with critical severe COVID-19 (32). More interestingly it was shown, 107 in ACE2 transgenic mouse model, that the blockade of TLR2 pathway allowed protection 108 against the disease development and lethality induced by SARS-CoV infection (32).

Considering the important role of innate immune sensors, including TLR2, as potential 110 therapeutic targets in order to alleviate the development of hyper-inflammation and cytokine 111 storm associated with severe COVID-19, in the present study we analysed at molecular level, 112 the interaction between SARS-CoV-2 envelope protein E and human TLR2. Our findings 113 demonstrated that the SARS-CoV-2 E protein interacts with TLR2 receptor in a specific and 114 dose dependent manner in a solid-phase binding assay but also on the cell membrane of TLR2 115 positive cells, including primary human monocytes and macrophages. Moreover, using HEK-116 based TLR2 reporter cell lines, we also showed that E protein activates TLR2 signaling 117 pathway that culminate in the activation of NF-κB transcription factor and production of 118 inflammatory cytokines/chemokine including CXCL8.

The finding suggest considering the envelope protein E as a novel target for COVID- 

The specificity of E-TLR2 interaction was evaluated in a solid phase binding assay as The analysis of the binding of E protein to macrophages was analyzed by microscopy.

To this end macrophages (10 6 ) were incubated with GST or GST-E SARS-CoV-2 protein at 208 10µg/ml for 1 hour at 37°C PBS, BSA 0.5%, NaN 3 0.05%. Then, cells were washed 3 times 209 with PBS, BSA 0.5%, NaN 3 0.05% to remove unbound proteins. Then cells were washed 3 210 times with PBS, stained with Hoechst, and anti-GST-Alexa 488 (1/500) during 1 hour at room 211 temperature and washed 3 times with PBS, BSA 0.5%, NaN 3 0.05%. Finally, cells were fixed 212 with PFA 4% before imaging. Images were acquired using EVOS M700 (Invitrogen) at 40x 213 magnification. 

228 HEK-TLR2 cells (2,5.10 5 cells) were treated during 30 or 60 min with E protein (1 229 µg/ml) or, with GST (1µg/ml) or PAM 3 CSK 4 (10 ng/ml) as negative and positive controls 230 respectively. Then, cells were lysed and prepared for immunoblot as previously described 231 (35). 232 233 2.13 NF-kB assay using HEK-TLR2-Blue: 234 The capacity of E protein to activate NF-kB was tested by using HEK-TLR2-blue Differences in the means for the different groups were tested using one-way ANOVA 251 followed by Bonferroni post hoc test. A p-value <0.05 was considered statistically significant.

Statistical significance comparing different groups is denoted with * for p < 0.05, **p < 0.01, 253 ***p < 0.001, ns non-significant. 258 In order to analyse the capacity of SARS-CoV-2 envelope protein E to interact with 259 TLR2 at a molecular level, we tested in a solid phase assay the binding of various amounts of 260 E protein (1 ng/ml-1000 ng/ml) to a constant amount of pre-coated human recombinant TLR2

(1 μg/ml). The obtained results depicted in Figure 1 showed that E protein binds in a dose-262 dependent manner to TLR2. In contrast, no significant binding to TLR2 was observed when 263 the experiment was performed with GST, instead of E protein ( Figure 1A) . Further, we also 264 showed that E protein, but not GST used as control, is also able to bind to human primary 265 monocytes when analysed by flow cytometry (Figure 1B, C) and to human primary 266 macrophages when analysed by microscopy ( Figure 1D ). 267 Altogether, these results demonstrate that the SARS-CoV-2 envelope protein is able to 268 interact physically, in a dose-dependent manner with the human soluble recombinant TLR2 269 but also with cell membrane TLR2 expressed at the surface of primary human monocytes and 270 macrophages. 

285 by recruiting TLR2 pathway: 286 In order to study the biological consequences of E-TLR2 interaction, we tested the 287 capacity of E protein to stimulate the production of CXCL8 in a HEK cell lines-based assay 288 using cells stably transfected with the human TLR2 (HEK-TLR2) or TLR4 (HEK-TLR4) 289 receptors or HEK-null (transfected with empty plasmid). As previously shown by our group, 290 activation of TLR-dependent pathway in HEK cells lines stimulates the production of 291 measurable amount of CXCL8 chemokine, while other TLR-dependent cytokines including 292 TNF-α, IL-6, IL-10 where barely detectable. As consequence, the production of CXCL8 by 293 HEK cells lines was used as a marker of TLR response (36). Results presented in figure 3A   294 show that E protein from SARS-CoV-2 (200ng/ml) stimulates the production of CXCL8 in 295 TLR2-expressing HEK cell lines, while GST or GST-Nef, two unrelated SARS-CoV-2 gene 296 products, used as controls, do not stimulate significant production of CXCL8 when used at 297 concentrations up to 1 µg/ml ( Figure 3A) . As additional controls, no production of CXCL8 

Taking into account the data obtained with HEK-TLR2 cell line, we tested the 309 capacity of E protein to activate the production of CXCL8 in human primary monocytes and 310 macrophages. To this end, human monocytes and macrophages were stimulated by increasing 311 concentrations of E protein (1 ng/ml to 200 ng/ml) for 20 hours and CXCL8 was quantified 312 by ELISA as described above. The obtained results showed that E protein stimulated the 313 production of CXCL8 in both primary human monocytes and macrophages ( Figure 3E) . 314 In line with these results, we also showed that treatment of primary human 315 macrophages, during 20 hours, with infectious SARS-CoV-2 viral particles also resulted in 316 the production of CXCL8 in cell supernatants ( Figure 3F) . It is interesting to note that Figure S1) . 322 Altogether, our results showed that SARS-CoV-2 E protein, by recruiting, at least, 323 TLR2 pathway stimulated the production of CXCL-8. RelA/p65, c-Rel, RelB, p50 and p52 (39). At the inactivated state heterodimeric NF-kB is 352 present in the cytoplasm in association with its inhibitor IkB. In order to be activated, NF-kB 353 must be phosphorylated on its subunits p65 and p50, but also on its inhibitor subunit IkB, thus Figure 5A lanes 3 and 4) . Only a small phosphorylation of p65 was 362 observed in unstimulated cells (Figure 5A lane 2) and in cells stimulated with GST protein 363 (Figure 5, lanes 5 and 6) . As expected, a strong phosphorylation was obtained following 364 stimulation with PAM 3 CSK 4 (Figure 5A lane 7) . 365 Then, the effect of E protein on the activation of NF-kB was further characterized in a (Figure 5 B) . As negative control, no significant SEAP 376 enzymatic activity was observed in supernatants of unstimulated HEK-TLR2 cells (Figure 5 377 B). 378 Altogether, these results showed that SARS-CoV-2 E envelope glycoprotein is able to 6B) . However, the apparent inhibition observed at 10 µM of the inhibitor is 417 further related to the cytotoxic effect of 10µM concentration of RO318220 as evaluated by the 418 cytotoxicity assay measuring LDH release, a signature of cell death (data not shown).

Taken together, our results demonstrated the direct physical interaction between the E 420 envelope protein of SARS-CoV-2 and the TLR2. This interaction engages the activation of 421 TLR2 pathway leading to the activation of the transcription factor NF-kB which seems to 422 play, in contrast to ERK1/2 and P38 MAP kinases, a major role in the production of CXCL8 CoV-2 activates TLR2 pathway leading to the activation of the transcription factor NF-κB 437 which seems to play a major role in the production of CXCL8 chemokine, in contrast to 438 ERK1/2 and P38 MAP-kinases whose inhibition only results in partial inhibition of CXCL8.

TLR2 was originally described to recognize ligands from bacterial origins (43-46) that 440 include diacyl and triacylglycerol moieties, proteins and polysaccharides. However, it is 441 currently assumed that recognition of TLR2 is not limited to bacterial ligand but concern a 442 broader set of molecules including viral proteins (review in (47) pocket of TLR2. In addition, it has been reported that E protein also exists in the form of 461 homo-oligomeric multimers (15, 49, 50) demonstrates that this activation is essential for CXCL8 production in HEK-TLR2 cell line.

The partial inhibition obtained in the presence of P38 and ERK1/2 MAPkinases inhibitors is (53). Similarly, type I interferon production was also observed following pDCs 487 interaction with SARS-CoV (53) and SARS-CoV-2 (54). Accordingly, in order to escape 488 from TLR-mediated immunity, viruses have developed several strategies to interfere with 489 signal transduction downstream of TLR pathways (52, 55). In contrary, dysregulated 490 activation of TLR pathway has been associated with enhanced pathogenesis. This is the case 491 for TLR4 pathway which is involved in pathogenesis of IAV, EBOV, and DENV infections 492 while treatment with TLR4 antagonists (Eritoran) reduced cytokine/chemokine production 493 and alleviate disease symptoms (56). Other viruses are taking advantage of TLR pathway to 494 their own benefits. Our group and other have shown that HIV-1, through its Tat protein, 495 activates TLR4 pathway leading to the upregulation of several immunosuppressive factors 496 including IL-10, PD-L1 and [57] [58] [59] . This is also the case for measles virus which 497 subvert TLR2 pathway by its hemagglutinin (H) protein in order to upregulate the expression 498 of its own entry receptor CD150 (60). In the case of SARS-CoV-2, data from Zheng and 499 colleagues suggested that TLR2 pathway is involved in disease pathogenesis rather than viral 500 control (31). 

Characteristics of SARS-CoV-2 and COVID-19

Structural and functional properties of SARS-532

CoV-2 spike protein: potential antivirus drug development for COVID-19

Functional assessment of cell entry and receptor usage 535 for SARS-CoV-2 and other lineage B betacoronaviruses

Coronavirus envelope protein: current knowledge

Exceptional flexibility in the sequence requirements for 539 coronavirus small envelope protein function

Coronavirus pseudoparticles 541 formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes

Coronavirus 544 envelope (E) protein remains at the site of assembly

A severe acute respiratory syndrome coronavirus that lacks 547 the E gene is attenuated in vitro and in vivo

Absence of E protein arrests 549 transmissible gastroenteritis coronavirus maturation in the secretory pathway

Immunization with an attenuated severe acute respiratory syndrome coronavirus 553 deleted in E protein protects against lethal respiratory disease

The missing link in coronavirus assembly. Retention of the avian 555 coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and 556 physical interaction between the envelope and membrane proteins

Infectious bronchitis virus E protein is targeted to the Golgi 559 complex and directs release of virus-like particles

Efficient assembly and release of SARS coronavirus-like particles by a 561 heterologous expression system

Coronavirus virulence genes with main 564 focus on SARS-CoV envelope gene

Severe acute 567 respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 568 inflammasome

SARS-CoV and IFN: Too Little, Too Late

2021. Type I and III interferon responses in SARS-CoV-2 infection

Monocyte-driven atypical cytokine storm and 54

Soumelis 683 V. 2021. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via 684 UNC93B and IRAK4. The Journal of experimental medicine 218

Innate immune sensing of coronavirus and viral 686 evasion strategies

HIV-1 Tat 690 protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor 691 alpha-and toll-like receptor 4-mediated mechanisms

Planes R, Bahraoui E. 2013. HIV-1 Tat protein induces the production of IDO in human 695 monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation

Hemagglutinin protein of wild-699 type measles virus activates toll-like receptor 2 signaling

Is IL-6 a key cytokine target for therapy in COVID-19?

Interleukin-6 Receptor Inhibition in Covid-19 -Cooling 703 the Inflammatory Soup

COVID-19: 705 consider cytokine storm syndromes and immunosuppression

SARS-CoV-2 triggers an MDA-5-708 dependent interferon response which is unable to control replication in lung epithelial cells

SARS-CoV-2, SARS-CoV-1, and HIV-1 derived 711 ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-712 classical pathway

CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor 715 signaling in epithelial cells

Epidemiological and clinical characteristics of 99 cases of 2019 novel 718 coronavirus pneumonia in Wuhan, China: a descriptive study

720 Dysregulation of Immune Response in Patients With Coronavirus

Clinical infectious diseases : an official publication of the Infectious Diseases Society of 722

Soluble recombinant 728 human TLR2 (100 µl at 1 µg/ml) were coated in 96 plates. After saturation, various amounts 729 of E-GST protein (1 ng/ml-1000 ng/ml) were added for 2 hours at 37°C. TLR2 E-GST 730 complexes were revealed by a solution of anti-GST-sera follow by anti-anti-GST conjugated 731 to HRP. (B) Primary human monocytes were

CoV-2 protein. Cells were stained with anti-GST (1/1000). Data were acquired using 733

One representative experiment is shown. (C) Quantification of SARS-CoV-2 E 734 protein or GST control binding to human monocytes out of from 3 different experiments 735 acquired on FACScalibur. (D) Primary human macrophages were incubated with 10 µg/ml of 736 GST or GST-E SARS-CoV-2 protein. Cells were stained with anti-GST (1/500)

Figure 2: PAM 2 CSK 4 and PAM 3 CSK 4 interfere with SARS-CoV-2 E binding to 740 TLR2: The specificity of E-TLR2 interaction was evaluated by testing the capacity of TLR2 741 ligands (A) PAM 2 CSK 4 (0.1-10 µM) and (B) PAM

Figure 3: E protein stimulate the production of CXCL8 chemokine in a TLR2-745 dependent manner: (A) HEK-TLR2 cell line were stimulated with E protein (200ng/ml), 746 GST (10-1000ng/ml) or GST-nef (10-1000ng/ml)

chemokine production in the cell supernatants was quantified by ELISA. (B) Production of 748 CXCL8 in cell supernatants of HEK-TLR2 cells stimulated by escalating concentrations of E 749 protein (1-300ng/ml). (C-D) Production of CXCL8 in cell supernatants of

cell lines stimulated with E protein (1-100ng/ml) or with PAM 3 CSK 4

Primary human monocytes and macrophages were stimulated with E protein (1-200ng/ml)

After 20h of treatment cell supernatant was collected and 754 CXCL8 chemokine production in the cell supernatants was quantified by ELISA. (F) Primary 755 human macrophages were infected with NeonGreen SARS-CoV-2 virus

ng/ml) or PAM 3 CSK 4 (10 ng/ml) were used as 757 positive control. After 20h of treatment cell supernatant was collected and CXCL8 chemokine 758 production in the cell supernatants was quantified by ELISA